

Special Issue

The Promise of Induced Pluripotent Stem Cells in the Biomedical Research 2.0

Message from the Guest Editor

More than a decade ago, the Japanese scientist Shinya Yamanaka showed that it is possible to convert adult cells into a state similar to that of pluripotent stem cell. These cells, named induced pluripotent stem cells (iPSCs), are similar to embryonic stem cells (ES) and are considered a very promising tool in the field of regenerative medicine. iPSCs, like ES cells, are self-renewing and pluripotent. Furthermore, because iPSCs are obtained from adult cells in vitro, they do not raise the ethical and legal problems associated with the use of ES cells. Because they are generated from the patient, the likelihood of rejection in autologous therapies is believed to be much lower. This Special Issue will address the applications of iPSCs, putting a special emphasis on the investigation of the physiopathogenic mechanisms behind diseases and the search for new therapies against them. Therefore, contributions by experts in the field, in the form of original articles and reviews, are most welcome.

- induced pluripotent stem cells
- drug discovery
- cell modelling
- cell therapy
- personalized medicine
- tissue engineering

Guest Editor

Dr. M. Esther Gallardo

Head of Translational Research with iPS Cells Group, Research Institute Hospital 12 de Octubre, i+12, Madrid, Spain

Deadline for manuscript submissions

closed (30 April 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/120502

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).